NEW HAVEN, Conn., May 11, 2017 /PRNewswire/ -- Biohaven
Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced
the closing of its previously announced initial public offering of
9,900,000 common shares at a price to the public of $17.00 per share. All of the shares in the
offering were sold by Biohaven. In connection with the
initial public offering, the underwriters exercised in full their
option to purchase an additional 1,485,000 common shares from
Biohaven. As a result, the total initial public offering size
was 11,385,000 common shares. The aggregate gross proceeds to
Biohaven from the offering, before deducting the underwriting
discounts and commissions and offering expenses, were approximately
$193.5 million. The common
shares began trading on the New York Stock Exchange on May 4, 2017 under the ticker symbol
"BHVN."
Morgan Stanley, Piper Jaffray
& Co. and Barclays Capital acted as joint book-running managers
for the offering. William Blair
acted as lead manager. Needham & Company acted as
co-manager.
The offering was made only by means of a prospectus. A
copy of the final prospectus related to the offering may be
obtained from the offices of Morgan Stanley & Co. LLC,
Attention: Prospectus Department, 180 Varick Street, 2nd Floor,
New York, New York 10014; or from
Piper Jaffray & Co., Attention:
Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at
(800) 747-3924, or by email at prospectus@pjc.com; or from Barclays
Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717,
telephone: (888) 603-5847, e-mail:
Barclaysprospectus@broadridge.com.
A registration statement relating to these securities was
declared effective by the Securities and Exchange Commission (the
"SEC") on May 3, 2017. Copies of the
registration statement can be accessed through the SEC's website at
www.sec.gov. This press release shall not constitute an offer to
sell, or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Biohaven
Biohaven is a clinical-stage biopharmaceutical company with a
portfolio of innovative, late-stage product candidates targeting
neurological diseases, including rare disorders. Biohaven has
licensed intellectual property from companies and institutions
including Bristol-Myers Squibb Company, AstraZeneca AB,
Yale University, Catalent, ALS
Biopharma LLC and Massachusetts General Hospital. Biohaven is
a company organized under the laws of the British Virgin Islands and its United States operations are based in
New Haven, Connecticut.
Contact
Dr. Vlad
Coric
Chief Executive Officer
Biohaven Pharmaceutical Holding Company Ltd.
Phone: (203) 404-0410
Email: vlad.coric@biohavenpharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biohaven-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-300456629.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.